Editorial: Mergers mean less competition, more costs

Cara Livernois | May 31, 2016 | Health Exec | Quality

An editorial in the Los Angeles Times discusses how "lower prices, better quality” might be something we hear from healthcare providers.

But will healthcare providers live up to this promise? Sadly, the data says something entirely different. In fact, hospital and insurance mergers almost always lead to higher costs, lower efficiencies and less innovation for the simple fact that mergers reduce competition.

Around the web

Cardiovascular Business

FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare

From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.

Cardiovascular Business

Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.

Editorial: Mergers mean less competition, more costs

Related Content

Around the web